Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10 Other Current Liabilities

As of the most recent data (March 2026), CYCCP shows a other current liabilities of $540K. That compares with $440 in the prior-year period — up 124037.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CYCCP's other current liabilities is now $540K (was $440) — a 124037.9% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10 is outperforming or lagging.

Tracking CYCCP's other current liabilities over time shows whether Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10 is scaling, shrinking, or reshaping that part of the business. The current reading is $540K That compares with $440 in the prior-year period — up 124037.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current liabilities page, Stockcircle has Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current liabilities (currently $540K) with ownership activity and broader fundamentals.

Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10's other current liabilities is $540K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.